Pathology: breast cancer - adjuvant; es-BC - HER2 positive - (neo)adjuvant (NA); es-BC - HR positive - (neo)adjuvant (NA);
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | es-BC - HR positive - (neo)adjuvant (NA) | ||
| ATEMPT, 2021 | Harbeck (TDM1 plus ET), 2017 | Harbeck (TDM1 plus ET), 2017 | ||
| trastuzumab emtasine plus endocrine therapy | 3 | T1 | T1 | T1 |
| trastuzumab based treatment | 0 | T0 | ||
| trastuzumab plus endocrine therapy | 0 | T0 | T0 |